Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P05549

UPID:
AP2A_HUMAN

ALTERNATIVE NAMES:
AP-2 transcription factor; Activating enhancer-binding protein 2-alpha; Activator protein 2

ALTERNATIVE UPACC:
P05549; Q13777; Q5TAV5; Q8N1C6

BACKGROUND:
The protein Transcription factor AP-2-alpha, known for its sequence-specific DNA-binding capability, is integral to regulating transcription of genes crucial for developmental processes. It interacts with viral and cellular enhancer elements, activating or suppressing genes vital for proper morphological development and functioning of various organs.

THERAPEUTIC SIGNIFICANCE:
Mutations in the gene encoding Transcription factor AP-2-alpha are responsible for Branchiooculofacial syndrome. This genetic association underscores the therapeutic potential of targeting this protein in treating the syndrome, offering hope for advancements in genetic therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.